# Clinical Trials Data EGFR - Document 114

# Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT02125240

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Pathologically confirmed lung adenocarcinoma after surgical resection\n\* Stage II-IIIA disease according to 7th edition of TNM staging\n\* Patients must harbor sensitive EGFR gene mutation (19/21)\n\* Received four cycles of platinum-based adjuvant chemotherapy.There are many different kinds of chemotherapy regimens including vinorelbine, gemcitabine, docetaxel, paclitaxel, pemetrexed plus cisplatin or carboplatin.The first cycle of chemotherapy with cisplatin dose of 75 mg / m2 \u00b1 10% or carboplatin AUC = 5 \u00b1 10% to calculate the dose of chemotherapy\n\nExclusion Criteria:\n\n\* Previous systemic anti-tumor therapy, including chemotherapy or targeted therapy(Including but not limited to monoclonal antibodies, small molecule tyrosine kinase inhibitor, etc\n\* Presence of metastatic disease\n\* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ\n\* Any unresolved chronic toxicity from previous anticancer therapy\n\* Received antitumor radiation therapy (except for the stage IIIA N2 patients who received adjuvant radiotherapy after surgery)",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
A patient with an EGFR gene mutation \*could\* be eligible, but more information is needed. The criteria specifies they must harbor a \*sensitive\* EGFR gene mutation (19/21). Simply having \*any\* EGFR mutation isn't enough; it must be one of the specific types (exon 19 deletion or exon 21 L858R substitution) that are known to respond to targeted therapies. If the patient has one of these sensitive mutations and meets all other inclusion criteria and none of the exclusion criteria, then they would be eligible.